• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • Academy
  • FAQ
  • News
  • Blog
  • Europe
    • United Kingdom
    • Spain
    • Italy
    • Portugal
    • Brazil
    • Colombia
    • Ecuador
    • Mexico
    • Argentina
    • Latin America
    • UAE
Veritas

Veritas

  • Services and Test
        • Preventive Medicine
          • myGenome
          • myGeneticRisk
          • myHealthScore
          • myPharma
        • Perinatal Medicine
          • myPrenatal
          • myNewborn
          • myBabyHealth
          • PregnancyLoss
          • PrenatalWES
        • Diagnostic Genetics Services
          • CardioRisk
          • CancerRisk
          • GenomeDx
          • ExomeDx
          • Targeted Panels
        • Genetic Counselling
          • Genetic Counselling
  • Medical Professionals
  • Partners
  • Experiences
  • About Veritas
  • CONTACT
LlámanosLlámanos
CALL US!
  • Europe

  • United Kingdom

  • Spain

  • Italy

  • Brazil

  • Portugal

  • Colombia

  • Ecuador

  • Mexico

  • Argentina

  • Latin America

  • Services & Test
    • Preventive Medicine
      • myGenome
      • myGeneticRisk
      • myHealthScore
    • Pregnancy & Early Childhood
      • myPrenatal
      • myNewborn
      • myBabyHealth
      • PregnancyLoss
    • Genetics Diagnostics
      • CardioRisk
      • CancerRisk
      • GenomeDx
      • ExomeDx
      • Targeted Panels
    • Genetic Counseling
  • Medical Professionals
  • Partners
  • Experiences
  • About Veritas
  • Academy
  • FAQ
  • News
  • Blog
  • Contact
  • Description

Description

This service is an advanced genetic test that analyses 17 genes known to significantly increase an individual’s risk of developing hereditary breast, gynaecological and colorectal cancer, among others.

£299

Order the test

The test is particularly indicated for:

Females with breast or ovarian cancer diagnosis, males with breast cancer diagnosis or individuals presenting any cancer type related to Lynch Syndrome.

Family history related to the conditions described above.

The test includes 17 genes related to hereditary breast and ovarian cancer together with Lynch Syndrome, with strong level of evidence as established in NCCNb guidelines, for which specific medical management is defined.

Adding Lynch Syndrome genes to the panel enables the detection
of an additional 10%-15% of the hereditary ovarian cancer cases

uksupport@veritasint.com

Footer

  • facebook
  • youtube
  • twitter
  • instagram
  • linkedin

VERITAS INTERCONTINENTAL – CALLE ORENSE 58, 2ºC-D, 28020 MADRID, ESPAÑA – CIF B88132907 – AUTHORIZED MEDICAL CENTER Registration Nº CS20242

  • Privacy policy and Legal Notice
  • General contracting conditions
  • Cookies Policy